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Abstract
Background: Familial mediterranean fever (FMF) is a recessively inherited disease characterized
by recurrent crises of fever, abdominal, articular and/or thoracic pain. The most severe
complication is the development of renal amyloidosis. Over 35 mutations have been discovered so
far in the gene responsible for the disease, MEFV. This article aims at determining a correlation
between the MEFV genotype and the occurence of amyloidosis in FMF patients, in addition to the
study of the modifying effects of the SAA1 (type 1 serum amyloid A protein) and MICA (Major
Histocompatibility Complex (MHC) class-I-chain-related gene A) genes on this severe
complication.
Methods: Fourteen MEFV mutations were screened and the SAA1 and MICA polymorphisms tested
in 30 FMF patients with amyloidosis and 40 FMF patients without amyloidosis.
Results: The M694V and V726A allelic frequencies were, respectively, significantly higher and
lower in the group with amyloidosis, compared to the control FMF group. The beta and gamma
SAA1 alleles were more frequently encountered in the group without amyloidosis, whereas the
alpha allele was significantly more observed in FMF patients with amyloidosis (p < 0.025). All the
MICA  alleles were encountered in both patients' groups, but none of them was significantly
associated with amyloidosis.
Conclusions: The results suggest a protective effect of the SAA1 beta and gamma alleles on the
development of amyloidosis and show the absence of a MICA modifying effect on amyloidosis
development. Testing these polymorphisms on a larger sample will lead to more definite
conclusions.
Background
Familial mediterranean fever (FMF, MIM 249100) is a
recessively inherited disease mostly prevalent in Jews,
Armenians, Arabs and Turks [1]. It is characterized by
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recurrent bouts of fever, accompanied by serosal inflam-
mation, leading to abdominal, articular and/or thoracic
pain. The most severe complication of FMF is the develop-
ment of secondary renal amyloidosis, and two disease
phenotypes have been identified, wether amyloidosis
appears years after the appearance of the other clinical
signs (phenotype I), or wether it is the first or the only
FMF presenting sign (phenotype II), which is less frequent
[1,2]. Over 35 mutations [3] have been discovered so far,
in the gene responsible for the disease, MEFV [4,5]. The 5
most frequent mutations are M694V, M694I, V726A,
M680I and E148Q.
Correlation of FMF patients genotypes with the various
phenotypes of the disease, especially amyloidosis, has
been often studied. The latter complication has been often
associated with a specific mutation in exon 10, M694V,
especially at the homozygous state [6-11], while others
found that there was no specific genotype correlated with
the development of amyloidosis [12]. Moreover, 2 genes,
namely SAA1 (type 1 serum amyloid A protein) and MICA
(Major Histocompatibility Complex (MHC) class-I-chain-
related gene A) have been investigated in FMF patients
and were found to have an effect on amyloidosis and on
the course of the disease respectively. The genotype alpha/
alpha of the SAA1 gene was associated with a sevenfold
increase in the incidence of renal amyloidosis, especially
in patients homozygous for M694V [13,14], whereas the
MICA alleles A4 and A9 were associated with a dimin-
ished attacks frequency and an earlier age of onset, respec-
tively, notably in patients homozygous for M694V [15].
The purpose of the present article is to determine a corre-
lation between the MEFV genotype and the occurence of
amyloidosis in FMF patients, in addition to the study of
the modifying effects of the SAA1 and MICA genes on this
severe complication.
Methods
The main study group was composed of thirty Lebanese
and Jordanian amyloidosis affected FMF patients from 24
non-related families. Renal amyloidosis was detected
either by biopsy or persistent proteinuria. Thirteen of
these patients were either having regular renal dialysis or
had a renal transplantation. A comparative group was
composed of 40 FMF patients, either homozygous or
compound heterozygous for MEFV mutations, having an
age superior to 20 years old. These patients did not have
amyloidosis, nor did they have any sign of proteinuria,
and were not under any medication, including colchicine,
before the time of the study. Patients of both groups will-
ingly filled up a questionnaire form where clinical and
social information were recorded.
Blood samples were withdrawn from all the patients on
EDTA, and DNA was extracted from leucocytes by stand-
ard technique [16].
Fourteen mutations previously detected in the Lebanese
and Jordanian populations were screened (M694V,
M694I, V726A, M680I, E148Q, E167D, T267I, R761H,
P369S, A744S, F479L, I692del, M694del, K695R) as pre-
viously described [11,17].
SAA1 and MICA genes polymorphisms were tested in the
2 FMF patients' groups. The DNA fragment including the
SAA1 gene polymorphisms was amplified using the Saa1F
(5'-GCCAATTACATCGGCTCAG-3') and Saa1R (5'-
TGGCCAAAGAATCTCTGGAT-3') primers. The 2 poly-
morphisms of the SAA1 gene were determined with 2
restriction enzymes, BanI and BclI, that allowed the iden-
tification of the amino acids at positions 52 and 57,
respectively [18]. Valine/Alanine, Alanine/Valine and
Alanine/Alanine amino acids at positions 52/57 defined
respectively the alpha, beta and gamma SAA1 alleles.
The MICA transmembrane region polymorphism, which
is a polyalanine repeat, was tested by genotyping using
fluorescent dUTP (2'-deoxyuridine 5'-triphosphate) on an
ABI 310 genetic analyzer. Sequencing was performed
whenever needed to determine the different MICA alleles.
The primers used to amplify the exon 5 polymorphism
containing DNA fragment were Mica-5F (5'-CCTTTTTT-
TCAGGGAAAGTGC-3') and Mica-5R (5'-CCTTAC-
CATCTCCAGAAACTGC-3').
Chi-squared test was performed to test the significance of
differences in FMF crises frequency and in SAA1 genotypes
and MICA alleles distribution between the 2 groups of
FMF patients, with and without amyloidosis. A P value of
0.05 or less meant that the difference was statistically
significant.
Results
Fifty percent and 20 % of the 24 unrelated amyloidosis
affected FMF patients and of the control FMF group,
respectively, were consanguineous (p < 0.02). All amy-
loidosis affected FMF patients in this study were of the
phenotype I. Twelve of the unrelated amyloidosis affected
patients never took colchicine before the development of
renal amyloidosis, one patient was not taking it regularly,
3 of them stopped taking it after having taken it for some
years, in one case because of the inefficacy of the drug in
relieving the patient from painful crises.
Ages at the moment of diagnosis of FMF varied from 3 to
50 years, and from 7 to 44 years, in the groups of patients
with and without amyloidosis, respectively. Diagnosis
was mainly made between 20 and 35 years of age inBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/4
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patients without amyloidosis, whereas the disease mani-
fested earlier, mostly between 10 and 20 years, in patients
with amyloidosis (p < 0.005). Moreover, patients with
amyloidosis had a significantly higher crises frequency,
compared to the FMF control group (p < 0.02).
The genotypes of the FMF patients with and without amy-
loidosis are shown in table 1. The 6 siblings in the group
with amyloidosis were homozygous for M694V. The
M694V, V726A and M694I allelic frequencies were respec-
tively 67%, 12%, and 8% in the group of patients with
amyloidosis, and 25%, 39% and and 15% in patients
without amyloidosis (p < 0.001).
The alpha, beta and gamma SAA1 alleles were encoun-
tered in patients without amyloidosis, whereas only the
alpha and beta alleles were detected in amyloidosis
patients. Table 2 shows the allele combinations detected
in the patients. Once the beta/beta and beta/gamma gen-
otypes were grouped, the difference between the 2 groups
was significant (p < 0.05). Comparison of the alpha and
beta allelic frequencies in the 2 groups of patients was also
significant (p < 0.025). However, the distribution of the
SAA1  alleles among the M694V homozygous FMF
patients with amyloidosis was not different from the
M694V homozygous patients without amyloidosis.
All the different MICA alleles were encountered in both
patients' groups. Once the 2 groups were combined, no
specific MICA allele was significantly associated neither
with the age of onset of the disease, nor with the attacks
frequency. Moreover, no specific MICA genotype or allele
was significantly associated with the development of
amyloidosis (Table 3), even in the M694V homozygotes
subgroup.
Discussion
Familial mediterranean fever is a clinically heterogeneous
disease. The quite variable phenotypes among FMF
patients have suggested specific mutational effects as well
Table 1: Genotypes of the FMF patients with and without amyloidosis





















Table 2: Number of SAA1 genotypes observed in FMF patients with and without amyloidosis.
Genotypes Alpha/alpha Alpha/beta Beta/beta Beta/gamma* Total
FMF patients with amyloidosis 11 16 3 0 30
FMF patients without amyloidosis 10 15 11 4 40
T o t a l 2 13 11 4 4 7 0
*Once the genotypes beta/beta and beta/gamma are grouped, X2 = 6.789 (p < 0.05)BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/4
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as the presence of some genes that would affect the
appearance of the different clinical signs, especially amy-
loidosis. The significantly more important consanguinity
in the group with amyloidosis (p < 0.02), compared with
the control group, suggests a recessive modifying aspect of
this phenotype. The present study associates amyloidosis
with some aspects of disease severity, and with the specific
mutation M694V, although it points out the involvment
of other mutations in the occurence of this severe pheno-
type. Moreover, it associates SAA1 alleles with the pres-
ence or absence of amyloidosis, whereas MICA was not
found to have any association with amyloidosis.
The development of glomerular renal amyloidosis in FMF
patients, unlike the secondary amyloidosis that occurs in
other different diseases, was not previously associated
with the frequency, nor the severity of the febrile crises
[19]. The development of amyloidosis in patients having
never experienced FMF attacks (phenotype II) is in favor
of the lack of association between amyloidosis and FMF
severity. However, in the present study, amyloidosis
development in FMF patients has been significantly asso-
ciated with a beginning of the disease prior to 20 years old
(p < 0.005), and with a higher FMF crises frequency (p <
0.02), compared with the control FMF group, which
allowed the association of amyloidosis with FMF severity
in phenotype I patients.
Contradictory genotype-phenotype studies tried to associ-
ate amyloidosis with a specific mutation or genotype. The
M694V mutation, that has often been correlated with a
severe FMF phenotype, has also been correlated, espe-
cially at the homozygous state, with amyloidosis develop-
ment [6,7,9,14], whereas a study on Turkish families
presenting FMF patients with amyloidosis revealed that
the M694V mutation was not the only mutation present-
ing a risk for amyloidosis development [12]. In the
present study, a significant increase in the number of
patients homozygous for the M694V mutation was noted
in the group with amyloidosis (p < 0.001), compared to
all the other genotypes. In parallel, the M694V allelic fre-
quency was significantly higher and the V726A allelic fre-
quency significantly lower in the group with amyloidosis,
compared to the control FMF group (p < 0.001). However,
the simultaneous occurence of V726A with another muta-
tion such as M694V or M680I seems to modify the mild
effect of V726A, and thus increase the severity of the dis-
ease. Indeed, 3 FMF patients with amyloidosis were com-
pound heterozygous for V726A and M680I (Table 1). The
latter genotype was also previously encountered in FMF
patients with amyloidosis [7].
The serum amyloid protein (SAA) is an acute phase pro-
tein which serum level increases considerably during
inflammation and leads, by proteolytic cleavage, to amy-
loid A proteins, the major fibrillar proteins in secondary
amyloidosis [20]. Two isotypes, SAA1 and SAA2, with
quite homologous sequences have been distinguished,
and allelic forms of these isotypes have been identified
[21]. The SAA1 allelic forms have been associated with the
incidence of amyloidosis in different diseases and various
populations. The SAA1 alpha/alpha genotype has already
been associated with the occurence of amyloidosis in
Armenian FMF patients [13], whereas both the alpha
SAA1 allele and the alpha/alpha genotype were signifi-
cantly associated with this phenotype in Caucasian juve-
nile chronic arthritis patients [22]. In the present study,
the beta/beta and beta/gamma SAA1 genotypes, as well as
the alleles beta and gamma, were more frequently
encountered in the group without amyloidosis than in the
group with amyloidosis, whereas the alpha/alpha and the
alpha/beta genotypes, and hence the alpha allele were
much more observed in patients with amyloidosis (Table
2). This study shows therefore the association of the alpha
allele with this severe phenotype, as well as the protective
effect of the beta and gamma alleles on the development
of amyloidosis in FMF patients, an effect that was not
mentioned previously.
The MICA gene has been recently associated with different
inflammatory diseases. The MICA transmembrane exon 5
polymorphism consisting of a (GCT/AGC)n triplet repeti-
tion has been particularly studied. Five alleles have been
identified so far: A4, A5, A6, A9, corresponding to 4, 5, 6
and 9 repetitions and A5.1, corresponding to a 5 triplet
repetition and the insertion of one nucleotide (G/C).
MICA appears to be a susceptibility factor in many multi-
factorial diseases such as Behcet's disease [23], psoriatic
arthritis [24] and diabetes [25,26]. In FMF, the first mono-
genic disease associated with MICA, the latter was found
to have a modifying effect on the course of the disease,
namely on the attacks frequency and the age of onset, but
Table 3: Distribution of MICA alleles in the 2 groups of FMF patients, with and without amyloidosis (Non significant)
MICA alleles A4 A5 A5.1 A6 A9 Total
FMF patients with amyloidosis 7 13 12 19 9 60
FMF patients without amyloidosis 15 12 13 30 10 80
T o t a l 2 22 52 54 91 9 1 4 0BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/4
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not on its clinical manifestations [15]. As it was not, how-
ever, tested in FMF patients having developed renal amy-
loidosis, we tried to investigate any possible correlation
between the MICA polymorphism and this specific phe-
notype. The MICA alleles and genotypes were found in a
non-significant way in both FMF groups, with and with-
out amyloidosis. Hence, no clear cut association was
detected between any MICA allele or genotype and this
severe phenotype (Table 3). Moreover, the lack of associ-
ation between any MICA allele and the age of onset of the
disease on one hand, and the attack frequency on the
other hand, in the combined group of FMF patients, is in
contradiction with previously published results, that cor-
related the A4 and the A9 MICA alleles with a reduced fre-
quency of attacks and an early age of onset, respectively
[15]. Such observation could suggest either a weak effect
of MICA hidden by a stronger effect of MEFV or SAA1 gen-
otypes, or a possible varying effect of MICA on the course
of the disease in different populations, which could be
expected in the case of genes that have minor modifying
effects on a disease phenotype.
Conclusions
With the availability of the genetic FMF test, since the
cloning of the MEFV gene in 1997, and the automatic pre-
scription of colchicine to the confirmed patients, amy-
loidosis is being far less encountered. But the reason why
it develops in some patients, not in others, is still
unknown. The effect of the MEFV genotypes, mainly the
ones homozygous for the M694V mutation, seems evi-
dent, but there are definitely other modifying factors or
genes that play a role in the manifestation of amyloidosis.
In the present study, no association was found between
the MICA gene exon 5 polymorphism and the develop-
ment of renal amyloidosis in FMF patients, whereas the
alpha allele and the alpha/alpha genotype of the SAA1
gene were associated with this severe phenotype, and the
beta and gamma SAA1 alleles showed a protective effect
on its development. Testing these polymorphisms on a
larger sample will allow more accurate results and will
lead to more definite conclusions.
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